GeneDx is trading at $75.12, up 9.28%, in pre-market on October 21; its October 20 announcement of plans to add long-read whole genome sequencing is a likely catalyst, not confirmed attribution. - Shares closed at $68.74 on October 20, up 3.70%. - The technology may identify complex genetic variations traditional short-read sequencing can miss; an early-access program is planned by year-end. - Biotech sector pre-market strength may also be supportive.